Elephant in the room: natural killer cells don’t forget HIV either

Jost S, Reeves RK. Elephant in the room: natural killer cells don’t forget HIV either. Curr Opin HIV AIDS. 2025 Mar 1;20(2):109-116. doi: 10.1097/COH.0000000000000909. Epub 2025 Jan 17. PMID: 39773904; PMCID: PMC11802307.

A multi-omics spatial framework for host-microbiome dissection within the intestinal tissue microenvironment

Zhu B, Bai Y, Yeo YY, Lu X, Rovira-Clavé X, Chen H, Yeung J, Nkosi D, Glickman J, Delgado-Gonzalez A, Gerber GK, Angelo M, Shalek AK, Nolan GP, Jiang S. A multi-omics spatial framework for host-microbiome dissection within the intestinal tissue microenvironment. Nat Commun. 2025 Jan 31;16(1):1230. doi: 10.1038/s41467-025-56237-7. PMID: 39890778; PMCID: PMC11785740.

Increased Chemokine Production is a Hallmark of Rhesus Macaque Natural Killer Cells Mediating Robust Anti-HIV Envelope-Specific Antibody-Dependent Cell-Mediated Cytotoxicity

Nohara J, Evangelous T, Berry M, Beck W, Mudrak S, Jha S, Reeves RK, Wiehe KJ, Pollara J, Tomaras GD, Bradley T, Ferrari G. Increased Chemokine Production is a Hallmark of Rhesus Macaque Natural Killer Cells Mediating Robust Anti-HIV Envelope-Specific Antibody-Dependent Cell-Mediated Cytotoxicity. Pathog Immun. 2025 Jan 23;10(1):49-79. doi: 10.20411/pai.v10i1.734. PMID: 39911143; PMCID: PMC11792536.

Nonhuman primate antigenic cartography of SARS-CoV-2

Rössler A, Netzl A, Lasrado N, Chaudhari J, Mühlemann B, Wilks SH, Kimpel J, Smith DJ, Barouch DH. Nonhuman primate antigenic cartography of SARS-CoV-2. Cell Rep. 2025 Jan 28;44(1):115140. doi: 10.1016/j.celrep.2024.115140. Epub 2025 Jan 3. PMID: 39754717; PMCID: PMC11781863.

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2025 Jan;12(1):e13-e25. doi: 10.1016/S2352-3018(24)00247-9. Epub 2024 Dec 10. PMID: 39667379; PMCID: PMC11795396.

Identification of a novel neutralization epitope in rhesus AAVs

Dagotto, G., Fisher, J. L., Li, D., Li, Z., Jenni, S., Li, Z., Tartaglia, L. J., Abbink, P., & Barouch, D. H. (2024). Identification of a novel neutralization epitope in rhesus AAVs. Molecular therapy. Methods & clinical development32(4), 101350. https://doi.org/10.1016/j.omtm.2024.101350

Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial

Gray, G. E., Mngadi, K., Lavreys, L., Nijs, S., Gilbert, P. B., Hural, J., Hyrien, O., Juraska, M., Luedtke, A., Mann, P., McElrath, M. J., Odhiambo, J. A., Stieh, D. J., van Duijn, J., Takalani, A. N., Willems, W., Tapley, A., Tomaras, G. D., Van Hoof, J., Schuitemaker, H., … Imbokodo/HVTN 705/HPX2008 Study Group (2024). Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. Infectious diseases24(11), 1201–1212. https://doi.org/10.1016/S1473-3099(24)00358-X

Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques

Holmes S, Li H, Shen X, Martin M, Tuck R, Chen Y, Giorgi EE, Kirshner HF, Berry M, Van Italie E, Venkatayogi S, Martin Beem JS, Edwards RJ, Mansouri K, Singh A, Kuykendall C, Gurley T, Anthony Moody M, DeNayer N, Demarco T, Denny TN, Wang Y, Evangelous TD, Clinton JT, Hora B, Wagh K, Seaman MS, Saunders KO, Solomotis N, Misamore J, Lewis MG, Wiehe K, Montefiori DC, Shaw GM, Williams WB. Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques. Nat Commun. 2024 Nov 27;15(1):10302. doi: 10.1038/s41467-024-54753-6. PMID: 39604409; PMCID: PMC11603298.

Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques

Nkolola JP, Hope D, Guan R, Colarusso A, Aid M, Weiss D, Misamore J, Andersen H, Lewis MG, Williamson L, Carnahan RH, Crowe JE, Barouch DH.2024.Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques. J Virol98:e01429-24.https://doi.org/10.1128/jvi.01429-24

A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates

Vijayan, A., Vogels, R., Groppo, R., Jin, Y., Khan, S., Van Kampen, M., Jorritsma, S., Boedhoe, S., Baert, M., van Diepen, H., Kuipers, H., Serroyen, J., Del Valle, J. R., Broman, A., Nguyen, L., Ray, S., Jarai, B., Arora, J., Lifton, M., Mildenberg, B., … Zahn, R. (2024). A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates. Nature communications15(1), 9884. https://doi.org/10.1038/s41467-024-54289-9